Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women

David P. Rose, Steven M. Haffner, Jacques Baillargeon

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Breast cancer, the second most common cause of cancer-related deaths in American women, varies substantially in incidence and mortality according to race and ethnicity in the United States. Although the overall incidence of breast cancer among African-American (AA) women is lower than in white American women, this cancer is more common in young premenopausal AA women, and AA breast cancer patients of all ages are more likely to have advanced disease at diagnosis, higher risk of recurrence, and poorer overall prognosis. Epidemiological studies indicate that these differences may be attributable in part to variation in obesity and body fat distribution. Additionally, AA women more frequently exhibit breast cancer with an aggressive and metastatic phenotype that may also be attributable to the endocrine and metabolic changes associated with upper body obesity. These changes include both elevated estrogen and androgen bioactivity, hyperinsulinemia, and perturbations of the adipokines. Type 2 diabetes and the metabolic syndrome, which are more common in AA women, have also been associated with breast cancer risk. Moreover, each of the individual components of the syndrome has been associated with increased breast cancer risk, including low levels of the adipocytokine, adiponectin. This review explores the specific roles of obesity, body fat distribution (particularly visceral and sc adipose tissue), type 2 diabetes, metabolic syndrome, and adipocytokines in explaining the differential patterns of breast cancer risk and prognosis between AA and white American women.

Original languageEnglish (US)
Pages (from-to)763-777
Number of pages15
JournalEndocrine Reviews
Volume28
Issue number7
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Adiposity
African Americans
Breast Neoplasms
Adipokines
Body Fat Distribution
Obesity
Type 2 Diabetes Mellitus
Intra-Abdominal Fat
Adiponectin
Incidence
Hyperinsulinism
Androgens
Epidemiologic Studies
Neoplasms
Estrogens
Phenotype
Recurrence
Mortality

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. / Rose, David P.; Haffner, Steven M.; Baillargeon, Jacques.

In: Endocrine Reviews, Vol. 28, No. 7, 12.2007, p. 763-777.

Research output: Contribution to journalArticle

@article{8993396018194e69a332e1ff6d9e2d34,
title = "Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women",
abstract = "Breast cancer, the second most common cause of cancer-related deaths in American women, varies substantially in incidence and mortality according to race and ethnicity in the United States. Although the overall incidence of breast cancer among African-American (AA) women is lower than in white American women, this cancer is more common in young premenopausal AA women, and AA breast cancer patients of all ages are more likely to have advanced disease at diagnosis, higher risk of recurrence, and poorer overall prognosis. Epidemiological studies indicate that these differences may be attributable in part to variation in obesity and body fat distribution. Additionally, AA women more frequently exhibit breast cancer with an aggressive and metastatic phenotype that may also be attributable to the endocrine and metabolic changes associated with upper body obesity. These changes include both elevated estrogen and androgen bioactivity, hyperinsulinemia, and perturbations of the adipokines. Type 2 diabetes and the metabolic syndrome, which are more common in AA women, have also been associated with breast cancer risk. Moreover, each of the individual components of the syndrome has been associated with increased breast cancer risk, including low levels of the adipocytokine, adiponectin. This review explores the specific roles of obesity, body fat distribution (particularly visceral and sc adipose tissue), type 2 diabetes, metabolic syndrome, and adipocytokines in explaining the differential patterns of breast cancer risk and prognosis between AA and white American women.",
author = "Rose, {David P.} and Haffner, {Steven M.} and Jacques Baillargeon",
year = "2007",
month = "12",
doi = "10.1210/er.2006-0019",
language = "English (US)",
volume = "28",
pages = "763--777",
journal = "Endocrine Reviews",
issn = "0163-769X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women

AU - Rose, David P.

AU - Haffner, Steven M.

AU - Baillargeon, Jacques

PY - 2007/12

Y1 - 2007/12

N2 - Breast cancer, the second most common cause of cancer-related deaths in American women, varies substantially in incidence and mortality according to race and ethnicity in the United States. Although the overall incidence of breast cancer among African-American (AA) women is lower than in white American women, this cancer is more common in young premenopausal AA women, and AA breast cancer patients of all ages are more likely to have advanced disease at diagnosis, higher risk of recurrence, and poorer overall prognosis. Epidemiological studies indicate that these differences may be attributable in part to variation in obesity and body fat distribution. Additionally, AA women more frequently exhibit breast cancer with an aggressive and metastatic phenotype that may also be attributable to the endocrine and metabolic changes associated with upper body obesity. These changes include both elevated estrogen and androgen bioactivity, hyperinsulinemia, and perturbations of the adipokines. Type 2 diabetes and the metabolic syndrome, which are more common in AA women, have also been associated with breast cancer risk. Moreover, each of the individual components of the syndrome has been associated with increased breast cancer risk, including low levels of the adipocytokine, adiponectin. This review explores the specific roles of obesity, body fat distribution (particularly visceral and sc adipose tissue), type 2 diabetes, metabolic syndrome, and adipocytokines in explaining the differential patterns of breast cancer risk and prognosis between AA and white American women.

AB - Breast cancer, the second most common cause of cancer-related deaths in American women, varies substantially in incidence and mortality according to race and ethnicity in the United States. Although the overall incidence of breast cancer among African-American (AA) women is lower than in white American women, this cancer is more common in young premenopausal AA women, and AA breast cancer patients of all ages are more likely to have advanced disease at diagnosis, higher risk of recurrence, and poorer overall prognosis. Epidemiological studies indicate that these differences may be attributable in part to variation in obesity and body fat distribution. Additionally, AA women more frequently exhibit breast cancer with an aggressive and metastatic phenotype that may also be attributable to the endocrine and metabolic changes associated with upper body obesity. These changes include both elevated estrogen and androgen bioactivity, hyperinsulinemia, and perturbations of the adipokines. Type 2 diabetes and the metabolic syndrome, which are more common in AA women, have also been associated with breast cancer risk. Moreover, each of the individual components of the syndrome has been associated with increased breast cancer risk, including low levels of the adipocytokine, adiponectin. This review explores the specific roles of obesity, body fat distribution (particularly visceral and sc adipose tissue), type 2 diabetes, metabolic syndrome, and adipocytokines in explaining the differential patterns of breast cancer risk and prognosis between AA and white American women.

UR - http://www.scopus.com/inward/record.url?scp=37349024802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349024802&partnerID=8YFLogxK

U2 - 10.1210/er.2006-0019

DO - 10.1210/er.2006-0019

M3 - Article

C2 - 17981890

AN - SCOPUS:37349024802

VL - 28

SP - 763

EP - 777

JO - Endocrine Reviews

JF - Endocrine Reviews

SN - 0163-769X

IS - 7

ER -